Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

REFERENCES

• End D. W. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs 1999; 17: 241–258
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Windle J. J., Von Hoff D. D. Ras protein Farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 1999; 17: 3631–365
   PubMed Web of Science ®Google Scholar
• Sebti S. M., Der C. J. Searching for the elusive targets of Farnesyltransferase inhibitors. Nature Rev. Cancer 2003; 3: 945–951
   PubMed Web of Science ®Google Scholar
• Johnston S. R.D., Hickish T., Ellis P., Houston S., Kelland L., Dowsett M., et al. Phase II study of the efficacy and tolerability of two dosing regimens of the Farnesyltransferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 2003; 21: 2492–2499
   PubMed Web of Science ®Google Scholar
• Adjei A. A., Mauer A., Bruzek L., Marks R. S., Hillman S., et al. Phase II study of the Farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2003; 21: 1760–1766
   PubMed Web of Science ®Google Scholar
• Patnaik A., Eckhardt S. G., Izbicka E., Tolcher A. A., Hammond L. A., et al. A Phase I, pharmacokinetic, and biological study of the Farnesyltransferase inhibitor Tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin. Cancer Res. 2003; 9: 4761–4741
   PubMed Web of Science ®Google Scholar
• Siegel-Lakhai W. S., Crul M., Zhang S., Sparidans R. W., Pluim D., et al. Phase I and pharmacological study of the Farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br. J. Cancer 2005; 93: 1222–1229
   PubMed Web of Science ®Google Scholar
• Dy G. K., Bruzek L. M., Croghan G. A., Mandrekar S., Ehrlichman C., et al. A phase I trials of the novel Farnesyltransferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin. Cancer Res. 2005; 11: 1877–1883
   PubMed Web of Science ®Google Scholar
• Khuri F. R., Glisson B. S., Kim E. S., Statkevich P., Thall P. E., et al. Phase I study of the Farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res. 2004; 10: 2968–2976
   PubMed Web of Science ®Google Scholar
• Boguski M. S., McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643–654
   PubMed Web of Science ®Google Scholar
• Lowy D. R., Willumsen B. M. Function and regulation of ras. Annu. Rev. Biochem. 1993; 62: 851–591
   PubMed Web of Science ®Google Scholar
• Khosvari-Far R., Cox AD., Cato K., Der CJ. Protein prenylation: key to ras function and cancer intervention?. Cell Growth Differ. 1992; 3: 461–469
   PubMedGoogle Scholar
• Lancet J. E., Karp J. E. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003; 102: 3880–3889
   PubMed Web of Science ®Google Scholar
• Reuter C. W.M., Morgan M. A., Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 2000; 96: 1655–1669
   PubMed Web of Science ®Google Scholar
• Ridley A. J., Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389–399
   PubMed Web of Science ®Google Scholar
• Armstrong S. A., Hannah V. C., Goldstein J. L., Brown M. S. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl tp RhoB. J. Biol. Chem. 1995; 270: 7864–7868
   PubMed Web of Science ®Google Scholar
• Adamson P., Marshall C. J., Hall A., Tilbrook P. A. Post-translational modifications of p21rho proteins. J. Biol. Chem. 1992; 267: 20033–20038
   PubMed Web of Science ®Google Scholar
• Prendergast C. G., Khosravifar R., Solski P. A., Kurzawa H., Lebowitz P., Der C. J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995; 10: 2289–2296
   PubMed Web of Science ®Google Scholar
• Du W., Lebowitz P. F., Prendergast C. G. Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of geranylgeranylated RhoB. Mol. Cell Biol. 1999; 19: 1831–1840
   PubMed Web of Science ®Google Scholar
• Lebowitz P. F., Casey P. J., Prendergast C. G., Thissen J. A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 1997; 272: 15591–15594
   PubMed Web of Science ®Google Scholar
• Lebowitz P. F., Sakamuor D., Prendergast C. G. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachement. Cancer Res. 1997; 57: 708–713
   PubMed Web of Science ®Google Scholar
• Chen Z., Sun J., Pradines A., Favre G., Adnane J., Sebti S. M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 2000; 275: 17974–17978
   PubMed Web of Science ®Google Scholar
• Raponi M., Lowenberg B., Lancet J. E., Harosseau JL., Stone R., et al. Identification of molecular predictors of response to Zarnestra (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood 2004; 104: 246a
   Web of Science ®Google Scholar
• Lackner M. R., Kindt R. M., Carroll P. M., Brown K., Cancilla M. R., et al. Chemical genetics identifies Rab geranylgeranyltransferase as an apoptotic target of Farnesyltransferase inhibitors. Cancer Cell 2005; 7: 325–336
   PubMed Web of Science ®Google Scholar
• Basso A. D., Mirza A., Liu G., Long B. J., Bishop W. R., Kirschmeier P. The Farnesyltransferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTor signaling. J. Biol. Chem. 2005; 280: 31101–31108
   PubMed Web of Science ®Google Scholar
• Ashar H. R., James L., Gray K., Carr D., Black S., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. 2000; 275: 30451–30457
   PubMed Web of Science ®Google Scholar
• Ashar H. R., James L., Gray K., Carr D., McGuirk M., et al. The farnesyltransferase inhibitor SCH66336 induces a G2 → M or G1 pause in sensitive human tumor cell lines. Exper. Cell Res. 2001; 262: 17–27
   PubMed Web of Science ®Google Scholar
• Crespo N. C., Ohkanda J., Yen T. J., Hamilton A. D., Sebti S. M. The farnesyltransferase inhibitor FTI-2153 blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 2001; 276: 16161–16167
   PubMed Web of Science ®Google Scholar
• Feldkamp M. M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 1999; 18: 7514–7526
   PubMed Web of Science ®Google Scholar
• Gu W. Z., Tahir S. K., Wang Y. C., Zhang H. C., Cherian S. P., et al. Effect of novel CAAX peptidomimetic farnesyl transferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer 1999; 35: 1394–1401
   PubMed Web of Science ®Google Scholar
• Peters D. G., Hoover R. R., Gerlach M. J., Koh E. Y., Zhang H., et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404–1412
   PubMed Web of Science ®Google Scholar
• Reichert A., Heisterkamp N., Daley G. Q., Groffen J. Treatment of Bcr-ABl positive acute lymphoblastic leukemia in P190 transgenic mice with the Farnesyltransferase inhibitor SCH66336. Blood 2001; 97: 1399–1403
   PubMed Web of Science ®Google Scholar
• Zhu K., Gerbino E., Beaupre D. M., Mackley P. A., Muro-Cacho C., et al. Farnsyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 2005; 105: 4759–4766
   PubMed Web of Science ®Google Scholar
• Burgering B. M., Coffer P. J. Protein kinase B (c-AKT) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599–602
   PubMed Web of Science ®Google Scholar
• Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998; 10: 262–272
   PubMed Web of Science ®Google Scholar
• Klippel A., Escobedo M. A., Wachowicz M. S., Aoell G., Brown T. W., et al. Activation of phosphatidylinositol-3 kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell Biol. 1998; 18: 5699–5711
   PubMed Web of Science ®Google Scholar
• Grandage V. L., Gale R. E., Linch D. C., Khwaja A. PI3-kinase is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia 2005; 19: 586–594
   PubMed Web of Science ®Google Scholar
• Jiang K., Coppola D., Crespo N. C., Nicosia S. V., Hamilton A. D., Sebti S. M., Cheng J. Q. The phosphoinositide 3-OH/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell Biol. 2000; 20: 139–148
   PubMed Web of Science ®Google Scholar
• Carloni V., Vizzutti F., Pantaleo P. Farnesyltransferase inhibitor ABT-100 is a potent liver cancer chemopreventive agent. Clin. Cancer Res. 2005; 11: 4266–4274
   PubMed Web of Science ®Google Scholar
• Delmas C., End D., Rochaix P., Favre G., Toulas C., Cohen-Jonathan E. The Farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin. Cancer Res. 2003; 9: 6062–6068
   PubMed Web of Science ®Google Scholar
• Delmas C., Heliez C., Cohen-Jonathan E., et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer 2002; 100: 43–48
   PubMed Web of Science ®Google Scholar
• Oh S. H., Kim W. Y., Kim J. H., Younes M. N., El-Naggar A. K., et al. Identification of insulin-like growth factor binding protein-3 as a Farnesyltransferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin. Cancer Res. 2006; 12: 653–661
   PubMed Web of Science ®Google Scholar
• Gu W. Z., Jospeh I., Wang Y. C., Frost D., Sullivan G. M., et al. A highly potent and selective Farnesyltransferase inhibitor ABT-100 in preclinical studies. Anticancer Drugs 2005; 16: 1059–1069
   PubMed Web of Science ®Google Scholar
• Lancet J. E., Willman C. L., Bennett J. M. Acute myelogenous and aging: clinical interactions. Hematol. Oncol. North. Am. 2000; 14: 251–267
   PubMed Web of Science ®Google Scholar
• Stone R. M., Berg D. T., George S. L., Dodge R. K., Paciucci P. A., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548–553
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J., Guo C., Gojo I., Karp J. E. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over age 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk. Res. 2004; 28: 571–577
   PubMed Web of Science ®Google Scholar
• Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Leith C. P., Kopecky K. J., Chen I. M., Eijdems L., Slovak M. L., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999; 94: 1086–1099
   PubMed Web of Science ®Google Scholar
• Karp J. E., Lancet J. E., Kaufmann S. H., End D. W., Wright J. J., et al. Clinical and biological activity in the Farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-correlative trial. Blood 2001; 97: 3361–3369
   PubMed Web of Science ®Google Scholar
• Lancet J. E., Gojo I., Gotlib J., Feldman E. J., Greer J., et al. A phase II study of the Farnesyltransferase inhibitor Tipifarnib in elderly patients with previously untreated poor-risk acute myelogenous leukemia. Blood 2007; 109: 1387–1394
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Reiffers J., Lowenberg B., Thomas X., Huguet F., et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 study. Blood 2003; 102: 176a
   Web of Science ®Google Scholar
• Cortes J., Faderl S., Estey E., Kurzrock R., Thomas D., et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J. Clin. Oncol. 2005; 23: 2805–2812
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Albitar M., Cortes J. E., Estey E. H., Faderl S. H., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 2004; 22: 1287–1292
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Kantarjian H. M., Cortes J. E., Singhania N., Thomas D. A., et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase 1 setting. Blood 2003; 102: 4527–4534
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Fenaux P., Raza A., Mufti G., Aul C., et al. High-risk myelodysplastic syndrome (MDS): first results of international Phase 2 study with oral farnesyltransferase inhibitor R115777 (ZARNESTRA). Blood 2004; 104: 23a
   Web of Science ®Google Scholar
• Kurzrock R., Verstovsek S., Wright J. J., Pilat S. R., Cortes J. E., et al. Alternate week administration of the farnesyltransferase inhibitor Tipifarnib (Zarnestra, R115777) in patients with myelodysplastic syndrome: results of a Phase I study. Blood 2005; 106: 7082, (Abstr. 2521)
   Google Scholar
• Feldman E. J., Cortes J., Holyoake T. L., Simonsson B., DeAngelo D. J., et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood 2003; 102: 421a
   PubMedGoogle Scholar
• Cortes J., Albitar M., Thomas D., Giles F., Kurzrock R., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101: 1692–1697
   PubMed Web of Science ®Google Scholar
• Cortes J. E., Daley G., Talpaz M., O'Brien S., Garcia-Manero G., et al. Pilot study of SCH66336(lonafarnib), a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to Imatinib. Blood 2002; 100: 164a
   Web of Science ®Google Scholar
• Mesa R. A., Tefferi A., Gray L. A., Reeder T., Schroeder G., Kaufmann S. H. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003; 17: 849–855
   PubMed Web of Science ®Google Scholar
• Mesa R. A., Camoriano J. K., Geyer S. M., Kaufmann S. H., Rivera C. E., Ehrlichmann C., Tefferi A. A Phase 2 consortium (P2C) trial of R115777 (Tipifarnib) in myelofibrosis with myeloid metaplasia. Blood 2004; 104: 422a
   Web of Science ®Google Scholar
• Bollag G., Clapp D. W., Shih S., Adler F., Zhang Y. Y., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics 1996; 12: 144–148
   PubMed Web of Science ®Google Scholar
• Schubbert S., Lieuw K., Rowe S. L., Lee C. M., Li X. X., et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005; 106: 311–317
   PubMed Web of Science ®Google Scholar
• Side L. E., Emanuel P. D., Taylor B., Franklin J., Thompson P., Castleberry R. P., Shannon K. M. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267–272
   PubMed Web of Science ®Google Scholar
• Castleman R. P., Loh M., Jayaprakash N., Peterson A., Casey V., et al. Phase II window study of the Farnesyltransferase inhibitor R115777 (Zarnestra) in untreated juvenile myelomonocytic leukemia (JMML): a Children's Oncology Group study. Blood 2005; 106: 727a, (Abstr. 2587)
   Web of Science ®Google Scholar
• Gotlib J., Loh M., Lancet J. E., Vattikuti S., Quesada S., et al. Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): interim results. Blood 2003; 102: 3425a
   Web of Science ®Google Scholar
• Buresh A., Perentesis J., Rimsza L., Kurtin S., Heaton R., Sugrue M., List A. F. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia 2005; 19: 308–310
   PubMed Web of Science ®Google Scholar
• List A. F., Tache-Tallmadge C., Tate W., Glinsmann-Gibson B., Brown D., et al. Farnesyltransferase inhibitors (FTI) modulate beta-integrin affinity to promote homotypic and heterotypic adhesion of chronic myelomonocytic leukemia (CMML) cells. Blood 2003; 102: 427a
   Web of Science ®Google Scholar
• Beaupre D. M., Cepero E., Obeng E. A., Boise L. H., Lichtenheld M. G. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol. Cancer Ther. 2004; 3: 179–186
   PubMed Web of Science ®Google Scholar
• Bolick S. C.E., Landowski T. H., Boulware D., Oshiro M. M., Ohkanda J., et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistance myeloma cells. Leukemia 2003; 17: 451–457
   PubMed Web of Science ®Google Scholar
• Gomez-Benito M., Marzo I., Anel A., Naval J. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol. Pharmacol. 2005; 67: 1991–1998
   PubMed Web of Science ®Google Scholar
• Le Gouill S., Pellat-Deceunynck C., Harousseau J. L., Rapp M. J., Robillard N., Bataille R., Amiot M. Farnesyl transferase inhibitor R115777 induces apoptosis in human myeloma cells. Leukemia 2002; 16: 1664–1667
   PubMed Web of Science ®Google Scholar
• Shi Y., Gera J., Hsu J., Van Ness B., Lichtenstein A. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol. Cell Ther. 2003; 2: 563–572
   Google Scholar
• Alsina M., Fonseca R., Wilson E. F., Belle A. N., Gerbino E., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271–3277
   PubMed Web of Science ®Google Scholar
• Ravandi-Kashani F., Kantarjian H., Garcia-Manero G., O'Brien S., Verstovsek S., et al. Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). Proc. Am. Soc. Clin. Oncol. 2006; 24: 351s
   Web of Science ®Google Scholar
• Marcus A. I., Zhou J., O'Brate A., Hamel E., Wong J., et al. The synergistic cominbation of the Farnesyltransferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires functional tubulin deacetylase. Cancer Res. 2005; 65: 3883–3893
   PubMed Web of Science ®Google Scholar
• Cortes J., Garcia-Manero G., O'Brien S., Hernandez I., Rackoff W., et al. A Phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients with chronic myeloid leukemia in chronic phase (CP) who failed IM therapy. Blood 2004; 104: 289a
   Web of Science ®Google Scholar
• Cortes J., O'Brien S., Verstovek S., Daley G., Koller C., et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients with chronic myeloid leukemia after failure to imatinib. Blood 2004; 104: 288a
   Web of Science ®Google Scholar
• Hu L., Shi Y., Hsu J., Gera J., Van Ness B., Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126–3135
   PubMed Web of Science ®Google Scholar
• Yanamandra N., Colaco N. M., Parquet N. A., Buzzeo R. W., Boulware D., et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res. 2006; 12: 591–599
   PubMed Web of Science ®Google Scholar
• David E., Sun S. Y., Waller E. K., Chen J., Khuri F. R., Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005; 106: 4322–4329
   PubMed Web of Science ®Google Scholar
• Buzzeo R., Enkemann S., Nimmanapalli R., Alsina M., Lichtenheld M. G., Dalton W. S., Beaupre D. M. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin. Cancer Res. 2005; 11: 6057–6064
   PubMed Web of Science ®Google Scholar
• Prendergast G. C., Davide J. P., Lebowitz P. F., Wechsler-Reya R., Kohl N. E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyltransferase inhibitors. Cancer Res. 1996; 56: 2626–2632
   PubMed Web of Science ®Google Scholar
• Smith V., Rowlands MG., Barrie E., Workman P., Kelland LR. Establishment and characterization of acquired resistance to farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin. Cancer Res. 2002; 8: 2002–2009
   PubMed Web of Science ®Google Scholar
• Zhang B., Groffen J., Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 2005; 106: 1355–1361
   Google Scholar
• Del Villar K., Urano J., Guo L., Tamanoi F. A mutant form of protein Farnesyltransferase exhibits increase resistance to farnesyltransferase inhibitors. J. Biol. Chem. 1999; 27010–27017
   PubMed Web of Science ®Google Scholar
• Raz T., Mohammad A., Daley G. Q. Resistance to the farnesyl transferase inhibitor SCH66336 (Lonafarnib) caused by mutations in the target protein farnesyl transferase beta. Blood 2004; 104: 133a
   Web of Science ®Google Scholar
• Goemans B. F., Zwaan C. M., Harlow A., Loonen A. H., Gibson B. E.S., et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005; 106: 3532–3537
   PubMed Web of Science ®Google Scholar
• Raponi M., Belly R. T., Karp J. E., Lancet J. E., Atkins D., Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004; 4: 56, doi; 10.1186/1471-2407-4-56
   PubMedGoogle Scholar
• Toksoz D., Williams DA. Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction proteins. Oncogene 1994; 9: 621–628
   PubMed Web of Science ®Google Scholar
• Zheng Y., Olson M. F., Hall A., Cerione R. A., Toksoz D. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J. Biol. Chem. 1995; 270: 9031–9034
   PubMed Web of Science ®Google Scholar
• Foisner R., Traub P., Wiche G. Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin. Proc Natl Acad Sci USA 1991; 88: 3812–3816
   PubMed Web of Science ®Google Scholar
• Tsai M. Y., Wang S., Heidinger J. M., Shumaker D. K., Adam S. A., Goldman R. D., Zheng Y. A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science 2006; 311: 1887–1893
   PubMed Web of Science ®Google Scholar
• Raponi M., Zhang Y., Jatkoe T., Yu J., Lee G., et al. Gene expression profiling predictive of Tipifarnib (ZARNESTRA, R115777) response in patients with newly diagnosed acute myeloid leukemia. Blood 2005; 106: 781a
   Web of Science ®Google Scholar
• Fong L. G., Frost D., Meta M., Qiao X., Yang S. H., Coffinier C., Young S. G. A protein Farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311: 1621–1623
   PubMed Web of Science ®Google Scholar